Glaxo Continues To Chase HGSI
GlaxoSmithKline (NYSE:GSK) recently announced its intention to commence a tender offer to acquire the outstanding shares of Human Genome Sciences, Inc. (NASDAQ:HGSI) for a cash payment of $13 per share. Glaxo decided that it will not take part in the strategic review being conducted by Human Genome. We note that the tender offer will remain [...]
GlaxoSmithKline (NYSE:GSK) recently announced its intention to commence a tender offer to acquire the outstanding shares of Human Genome Sciences, Inc. (NASDAQ:HGSI) for a cash payment of $13 per share. Glaxo decided that it will not take part in the strategic review being conducted by Human Genome.
We note that the tender offer will remain open for 20 business days after its commencement. According to Glaxo, its offer provides Human Genome shareholders with the option to make their own decision … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards